Evidence map›Paper›PMID 30238202›Full record

ArticleDigestive diseases and sciences2018

Microbial Biomarkers in Patients with Nonresponsive Celiac Disease.

Liisa Viitasalo, Kalle Kurppa, Merja Ashorn, Päivi Saavalainen, Heini Huhtala, Sara Ashorn, Markku Mäki, Tuire Ilus, Katri Kaukinen, Sari Iltanen

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Digestive diseases and sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Current and emerging therapies for coeliac disease.Nature reviews. Gastroenterology & hepatology · 2021
    Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Liisa ViitasaloTampere Center for Child Health Research, University of Tampere and Tampere University Hospital, Arvo Ylpön katu 34, 33014, Tampere, Finland.
Kalle KurppaTampere Center for Child Health Research, University of Tampere and Tampere University Hospital, Arvo Ylpön katu 34, 33014, Tampere, Finland. kalle.kurppa@uta.fi.ORCID http://orcid.org/0000-0003-4757-2164
Merja AshornTampere Center for Child Health Research, University of Tampere and Tampere University Hospital, Arvo Ylpön katu 34, 33014, Tampere, Finland.
Päivi SaavalainenResearch Programs Unit, Immunobiology, and Department of Medical and Clinical Genetics, University of Helsinki, P.O. Box 21, Haartmaninkatu 3, 00014, Helsinki, Finland.
Heini HuhtalaFaculty of Social Sciences, University of Tampere, P.O. Box 100, 33014, Tampere, Finland.
Sara AshornTampere Center for Child Health Research, University of Tampere and Tampere University Hospital, Arvo Ylpön katu 34, 33014, Tampere, Finland.
Markku MäkiTampere Center for Child Health Research, University of Tampere and Tampere University Hospital, Arvo Ylpön katu 34, 33014, Tampere, Finland.
Tuire IlusDepartment of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, P.O. Box 2000, Tampere, 33521, Finland.
Katri KaukinenCeliac Disease Research Center, Faculty of Medicine and Life Sciences, University of Tampere, P.O. Box 100, 33014, Tampere, Finland.
Sari IltanenTampere Center for Child Health Research, University of Tampere and Tampere University Hospital, Arvo Ylpön katu 34, 33014, Tampere, Finland.
Tampere University Hospital · FITampere University · FIUniversity of Helsinki · FILapland Central Hospital · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsIn nonresponsive celiac disease (NRCD), the symptoms and duodenal damage persist despite a gluten-free diet. Celiac disease patients with persistent symptoms are found to have a dysbiotic microbiota. We thus hypothesized that increased seroreactivity to the serum gluten-sensitive microbial antibodies Saccharomyces cerevisiae (ASCA), Pseudomonas fluorescens-associated sequence (I2), and Bacteroides caccae TonB-linked outer membrane protein (OmpW) is associated with NRCD.

methodsASCA, I2 and OmpW were measured in 20 seronegative CD patients with persistent villous damage despite strict dietary treatment (NRCD group). Fifty-eight responsive patients served as CD controls (55 on gluten-free treatment) and 80 blood donors as non-CD controls.

resultsAt least one microbial marker was positive in 80% of NRCD patients, in 97% of untreated CD and 87% of treated CD patients, and in 44% of controls. NRCD patients had the highest frequency of ASCA positivity (65% vs 52, 20, and 0%, respectively) and also significantly higher ASCA IgA (median 14.5 U/ml) and IgG (32.5 U/ml) titers than treated CD patients (7.0 U/ml, 13.0 U/ml) and non-CD controls (4.5 U/ml, 5.8 U/ml). The frequencies of I2 and OmpW were lower in NRCD than in untreated CD (65% and 45% vs 86% and 59%, respectively), and I2 titers were higher in NRCD (median absorbance 0.76) and untreated (1.0) and treated (0.83) CD than controls (0.32). OmpW was elevated in untreated (1.1) and treated (0.94) CD patients compared with controls (0.79).

conclusionsSeropositivity and high titers of ASCA are associated with NRCD and might serve as an additional follow-up tool in CD.

Indexed as

Celiac DiseaseDiet, Gluten-FreeDuodenumDysbiosisAntibodies, BacterialBacteroidesBiopsyCorrelation of DataEndoscopy, GastrointestinalFemaleFinlandGastrointestinal MicrobiomeHumansImmunohistochemistryMaleMiddle AgedAntibodies, BacterialBacteroides caccaeMicrobiotaNonresponsive celiac diseasePseudomonas fluorescenceSaccharomyces cerevisiae

Identifiers

PMID30238202
OpenAlexW2891286582

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.